罗氏诊断购买AvanSci Bio公司组织分离ZL技术
美国时间2014年12月10日，罗氏诊断宣布与AvanSci Bio公司签署了一项收购协议，购买与高性能显微组织滑动式切片分离的相关产品，包括仪器、软件及研究人员使用的耗材，以及临床提取、具有较高精确度和纯度用于后续分子分析的特定区域，包括实时PCR、微阵列和测序。
AvanSci Bio正在申请包括自动MilliSect仪器的ZL技术。相比手动清扫方法和激光显微切割系统，这种独特的技术非常精确且易于使用、非常实惠。MilliSect系统的高特异性能够使一个肿瘤富集大于90%的样本用于分子分析。
“这种创新系统将扩大我们的诊断工具套件，让我们能联合诊断H&E染色通过高质量的样品制备测序分析。”罗氏组织诊断和测序解决方案负责人Dan Zabrowski说道：“这也将使我们能迎接肿瘤异质性的关键挑战。”
Roche Diagnostics purchases tissue dissection technology from AvanSci Bio
2014 /PRNewswire/ --Roche Diagnostics (SIX: RO, ROG； OTCQX: RHHBY) has signed a definitive Asset Purchase Agreement with AvanSci Bio for all products associated with the high performance microdissection of slide mounted tissue sections. The system consists of instrumentation, software and consumables used by researchers and clinicians to extract specific areas of tissue with high precision and purity for subsequent molecular analysis including real time PCR, microarrays and sequencing.
AvanSci Bio's patent-pending technology includes the automated MilliSect™* instrument. This unique technology is highly precise, easy to use, and very affordable when compared to manual dissection methods and laser microdissection systems. The MilliSect™ system's high specificity and quality enables a greater than 90% tumor enriched sample for molecular analysis. The system will be tested at select customer sites in 2015 as part of a broader development program for a future generation instrument.
"This innovative system will expand our diagnostic tool kit allowing us to link the diagnostic hematoxylin and eosin (H&E) stain with sequencing analysis through high quality sample preparation," said Dan Zabrowski, Head of Roche Tissue Diagnostics and Sequencing Solutions. "It will also enable us to meet the critical challenge of tumor heterogeneity."
Tumor tissue staining gives researchers and clinicians important information about both tissue context and spatial relationships and tumor heterogeneity (which stems from the evolution of multiple subclones within the tumor). Information obtained from stained areas enable researchers and clinicians to pinpoint and extract more precise regions of interest within the tissue, resulting in purer samples of sufficient quantity that can then be used for sequencing. In addition, the analytical sensitivity of sequencing improves with higher sample purity as does subsequent data analysis and interpretation.
"We are very pleased that Roche has decided to pursue this Asset Purchase Agreement with AvanSci Bio," said Rob Perry, CEO, AvanSci Bio. "We see Roche as the leader in tissue based diagnostics, molecular diagnostics and oncology, as well as tumor sample enrichment technology, which puts them in a unique position to maximize the impact our technology will have on the rapidly evolving field of sequencing and in improving patient care."
Roche continues to invest in the bridge between the anatomical pathology and genomics labs as researchers and clinicians increasingly rely on pure, tumor-enriched slide mounted tissue samples for sensitive and efficient molecular analysis. As the challenge of tumor heterogeneity is addressed through slide-based tissue diagnostic technologies and the analytical sensitivity of next generation sequencing improves, patients may benefit through more accurate and effective targeted therapies.
*The MilliSect™ instrument targets a 100mm2 to 100 µm2 level of resolution (what AvanSci refers to as " meso" dissection range).
-
财报
-
产品技术
-
企业风采
-
焦点事件
-
焦点事件
-
财报
-
焦点事件
